Specifically, a recent phase I clinical study ([47]) provided insights into the safety and potential efficacy of lorlatinib, a third-generation ALK inhibitor, both with and without chemotherapy, for the treatment of ALK-driven refractory or relapsed neuroblastoma. Here, ALK is linked to neuroblastoma.